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Introduction {#osp463-sec-0005}
============

According to the CDC National Health Survey conducted from 2009 to 1012, 40.2% of Mexican origin adult men and 45.2% Mexican origin adult women are obese [1](#osp463-bib-0001){ref-type="ref"}. More alarmingly, the rate of obesity has been steadily increasing. In the early 1980s, only 21% of Mexican Americans were obese. By the middle 2000s, the rate was close to 35%. Obesity has also been linked to a variety of chronic diseases, including diabetes, cardiovascular disease, and cancers [2](#osp463-bib-0002){ref-type="ref"}, [3](#osp463-bib-0003){ref-type="ref"}, [4](#osp463-bib-0004){ref-type="ref"}, [5](#osp463-bib-0005){ref-type="ref"}, [6](#osp463-bib-0006){ref-type="ref"}. Clearly, obesity and related chronic diseases have posed enormous threats to the health of Mexican Americans.

To reduce such huge burden, understanding the underlying molecular mechanisms of how body weight is gained and obesity is developed and consequently developing interventions and therapeutic agents that can facilitate weight loss and conquest obesity are critically needed. In the past several years, metabolomics has been introduced in the obesity research [7](#osp463-bib-0007){ref-type="ref"}. Metabolomic platforms quantify small‐molecule metabolites in biospecimens and can be used to evaluate the role of metabolic alterations in chronic disease. Because it takes into account genetic regulation, altered kinetic activity of enzymes, genomics and proteomics, metabolomics reflects changes in phenotype, and thereby function [8](#osp463-bib-0008){ref-type="ref"}, [9](#osp463-bib-0009){ref-type="ref"}. Thus, the application of metabolomics in obesity research can help elucidate the molecular mechanisms of obesity and weight gain. Using blood samples from 947 participants identified from three cohort studies, Moore et al. identified a total of 37 metabolites associated with body mass index (BMI) in a cross‐sectional analysis [10](#osp463-bib-0010){ref-type="ref"}. In a few other studies, several amino acids (e.g. branched‐chain and aromatic amino acids) were associated with an increased BMI and levels of these amino acids were later found to predict future diabetes risk [11](#osp463-bib-0011){ref-type="ref"}, [12](#osp463-bib-0012){ref-type="ref"}, [13](#osp463-bib-0013){ref-type="ref"}, [14](#osp463-bib-0014){ref-type="ref"}, [15](#osp463-bib-0015){ref-type="ref"}. Weight loss upon behavioral intervention was associated with changes in the blood metabolome [16](#osp463-bib-0016){ref-type="ref"}, [17](#osp463-bib-0017){ref-type="ref"}. In addition, Wahl et al. found that long‐term weight change was globally associated with serum metabolite concentrations [18](#osp463-bib-0018){ref-type="ref"}. However, none of those studies include Mexican American study participants. More importantly, none of those studies have investigated whether metabolites might predict future weight gain prospectively.

To fill the gap, we performed metabolic profiling in plasma samples from 300 healthy Mexican American women from Mano‐A‐Mano, the Mexican American Cohort study. The study subjects were randomly divided into two cohorts: training (N = 200) and testing (N = 100) cohorts. The training cohort had 200 and the testing cohort had 100 study subjects. The objectives were two‐folded. First, we examined cross‐sectional associations between metabolite levels with BMI at baseline; second, we investigated whether baseline metabolite levels predicted significant weight gain during a 5‐year follow‐up.

Materials and methods {#osp463-sec-0006}
=====================

Study population {#osp463-sec-0007}
----------------

The samples for the current study were drawn from participants in a large population‐based cohort of Mexican origin households recruited from the Houston‐area. This ongoing prospective cohort of 1^st^ and 2^nd^ generation Mexican origin immigrant households in Houston, Texas, was initiated in July 2001 and maintained by the Department of Epidemiology at the University of Texas MD Anderson Cancer Center. A detailed description of the sampling and recruitment strategy has been published previously [19](#osp463-bib-0019){ref-type="ref"}. Briefly, participants have been recruited through block walking in predominantly Mexican American neighborhoods, from community centers and local health clinics, and networking through currently enrolled participants. Of the identified eligible households, \~88% agreed to participate in the study. After written informed consent was obtained, trained bilingual research interviewers conducted a structured face‐to‐face interview lasting \~45 minutes, using a standardized and validated questionnaire in the participant\'s preferred language, either Spanish or English. The questionnaire elicited information on birthplace and residential history, social‐demographic characteristics, lifestyle behaviors, levels of physical activity, personal medical history, family history of chronic disease, acculturation, and occupational exposure. Participants have been actively followed up via annual telephone re‐contact to update body weight, selected exposures and new diagnosis of selected chronic diseases, including cancer, diabetes, and hypertension. Current study included 300 healthy female non‐smokers who have no major chronic diseases reported at baseline (e.g. hypertension, cardiovascular disease, diabetes, and cancer). BMI at baseline was calculated using measured height and weight data during the in‐person interview according to a standard protocol by trained interviewers. BMI during follow‐up was calculated using self‐reported weight and height at baseline. The study protocol was approved by the Institutional Review Board of The University of Texas M. D. Anderson Cancer Center.

Metabolic profiling {#osp463-sec-0008}
-------------------

Metabolomics profiles were obtained using Liquid chromatography triple quadrupole mass spectrometry (LC‐QQQ‐MS) at Northwest Metabolomics Research Center, University of Washington. Semi‐targeted metabolomics analysis was performed. Briefly, LC‐MS/MS was performed using an electrospray ionization source and the multiple‐reaction‐monitoring mode. A Sciex 5500 QTRAP triple quad MS system equipped with an Agilent 1200 ultra‐high‐pressure liquid chromatography system was utilized. The MS acquisition for each plasma sample (0.050 mL each) target a list of 156 metabolites. In addition, 2 isotope‐labeled standards were included in each sample run for quality control and comparisons with other studies or additional samples run at a different time. The average CV of relative intensities for instrument QC samples was 5.3% for the detected metabolites and the average CV of quantified metabolites using isotope‐labeled internal standards was 3%, indicating good reproducibility. The targeted 156 metabolites are selected from 25 key metabolic pathways, including Alanine, Aspartate, and Glutamate metabolism; Arginine and Proline metabolism; Butanoate metabolism; the Citrate cycle (TCA cycle); Cysteine and Methionine metabolism; Fatty acid metabolism; Glutathione metabolism; Glycine, Serine, and Threonine metabolism; Glycolysis/Gluconeogenesis; Histidine metabolism; Lysine biosynthesis; Lysine degradation; Nitrogen metabolism; Oxidative phosphorylation; Pentose phosphate pathway; Phenylalanine metabolism; Phenylalanine, Tyrosine, and Tryptophan biosynthesis; Purine metabolism; Pyrimidine metabolism; Pyruvate metabolism; Synthesis and degradation of ketone bodies; Tryptophan metabolism; Tyrosine metabolism; Valine, Leucine, and Isoleucine biosynthesis; and Valine, Leucine, and Isoleucine degradation. Certain metabolites are involved in multiple metabolic pathways. The raw data were processed using MultiQuant software (AB SCIEX) to integrate chromatographic peaks, and the data were visually inspected to ensure the quality of signal integration. The peak area was calculated for each individual metabolite.

Statistical analysis {#osp463-sec-0009}
--------------------

Log‐transformed metabolite data were used in the analysis. Missing values were assumed to be below the limits of detection, and these values were imputed with the compound minimum (minimum value imputation). Training and testing cohorts were analyzed separately, but using the same approach. First, we examined the effect of baseline BMI as continuous variables in relation to metabolite levels using linear aggression, adjusting for age, HbA1c, acculturation score, nativity, years of living in U.S., sedentary lifestyle, sitting time, and biospecimen storage time. The study participants were further grouped into 5 categories based on their BMI, including normal weight (\<25), overweight (25‐29.90), class I obesity (30‐34.90), class II obesity (35‐39.90), and class III obesity (40 and above). ANOVA analysis was performed to determine the relationship between baseline BMI category and metabolite levels. To assess whether associations were independent, we evaluated the pairwise correlations between all metabolites significantly associated with BMI. Metabolites whose pairwise correlations greater than 0.5 were considered highly correlated and to have possible redundancy.

During the 5‐year follow‐up, each study participant had at least 3 self‐reported body weights. Because the focus of this study was on weight gain, 15 study subjects who lost weight during follow‐up were excluded from further analysis. Among them, 10 were from the training cohort and 5 were from the testing cohort. To assess the levels of weight gain during the follow‐up, we created a variable, termed "significant weight gain", which was defined as increase in BMI by at least one category between the baseline and the follow‐up. The creation was based on several reasons. First, it was considered major weight gain in relation to the time horizon of the prediction comprising 5 years. Second, it seems high enough to exclude random variation in body weight while simultaneously allowing for some weight gain as natural part of the aging process. Last, self‐reported BMI was used during the follow‐up. Self‐reported BMI correlates reasonably well with measured BMI values in adults [20](#osp463-bib-0020){ref-type="ref"}, but misclassification is more common among Mexican‐American women than men [21](#osp463-bib-0021){ref-type="ref"}. Cox regression analysis was performed to assess the association of metabolite levels with significant weight gain, adjusting for co‐variates as appropriate. The results from two cohorts were compared. Significant Metabolites in both cohorts were noted. All analyses were performed with STATA software version 10.1 (STATA, College Station, TX) and the R statistical language version 3.2.2.

Results {#osp463-sec-0010}
=======

At baseline, 47.5 and 57.0% of study subjects in the training and testing cohorts were obese (Table [1](#osp463-tbl-0001){ref-type="table-wrap"}). The obesity prevalence was further increased to 58.0 and 63.0% during the follow‐up. The mean age was 40 for both training and testing cohorts. The two cohorts were comparable with regard to baseline HbA1c levels, nativity, years living in U.S., acculturation score, and sitting time. However, study participants in the training cohort were less likely to have a sedentary lifestyle than those in the testing cohort (81.5 vs 88.0%).

###### 

Basic characteristics of study participants in the training and testing cohorts

  Characteristics                      Training (n = 200)   Testing (n = 100)
  ------------------------------------ -------------------- -------------------
  BMI at baseline, mean (SD)           30.6 (5.9)           31.5 (6.0)
  BMI category at baseline (kg/m^2^)                        
  \<25.0                               32 (16.0%)           8 (8.0%)
  25.0‐29.9                            73 (36.5%)           35 (35.0%)
  30.0‐34.9                            54 (27.0%)           33 (33.0%)
  35.0‐39.9                            24 (12.0%)           14 (14.0%)
  40.0 and above                       17 (8.5%)            10 (10.0%)
  BMI at follow‐up, mean (SD)          31.8 (6.0)           32.6 (5.6)
  BMI category at last follow‐up                            
  \<25.0                               16 (8.0%)            5 (5.0%)
  25.0‐29.9                            68 (34.0%)           32 (32.0%)
  30.0‐34.9                            67 (33.5%)           33 (33.0%)
  35.0‐39.9                            30 (15.0%)           22 (22.0%)
  40.0 and above                       19 (9.5%)            8 (8.0%)
  HbA1C, mean (SD)                     4.9 (0.83)           4.9 (0.44)
  Follow‐up time (days)                                     
  mean (SD)                            990 (450)            1459 (326)
  median (range)                       957 (229‐1825)       1481 (932‐1825)
  Age at baseline                                           
  mean (SD)                            40 (10.7)            40 (10.7)
  median (range)                       38 (20‐72)           38 (21‐69)
  Nativity                                                  
  U.S.                                 35 (17.5%)           13 (13.0%)
  Mexico                               165 (82.5%)          87 (87.0%)
  Years living in U.S., mean (SD)      19.6 (13.9)          19.9 (14.0)
  Acculturation score, mean (SD)       2.25 (0.92)          2.10 (0.90)
  Sedentary lifestyle                                       
  no                                   38 (19.0%)           12 (12.0%)
  yes                                  162 (81.0%)          88 (88.0%)
  Sitting hours/day, mean (SD)         2.1 (1.0)            2.0 (1.0)

In the training and testing cohorts, we identified a total of 20 and 18 metabolites significantly associated with BMI at baseline after adjusting for age, HbA1c, acculturation score, nativity, years living in U.S., sedentary lifestyle, sitting time, and biospecimen storage time (Table [2](#osp463-tbl-0002){ref-type="table-wrap"}). Among them, 7 were observed in both training and testing cohorts, with effect sizes in the same direction and of similar magnitudes between the two cohorts. The specific metabolites, their effect size calculated per 1 unit BMI increase, and P value are shown in Table [3](#osp463-tbl-0003){ref-type="table-wrap"}. They were Methyl succinate, Asparagine, Urate, Kynurenic acid, Glycine, Glutamic acid, and Serine. Methyl succinate was the most significant metabolite in the training cohort (P = 0.001). Each 1 unit elevation in BMI was associated with a 4.75% and 3.82% decrease in standard deviation in Methyl succinate levels in the training and testing cohorts. In the pairwise analysis of 7 significant metabolites in the training cohort, the only highly correlated associations were observed between Methyl succinate and Asparagine (ρ = 0.965, P \< 0.001), Asparagine and Serine (ρ = 0.543, P \< 0.001), and Glycine and Serine (ρ = 0.513, P \< 0.001). Neither Glutamic acid, Kynurenic acid, nor Urate was highly correlated with any other metabolites. Similar associations were observed in the testing cohort.

###### 

Association of metabolites with BMI at baseline in the training and testing cohorts[\*](#osp463-note-0001){ref-type="fn"}

  [Training]{.ul}     [Testing]{.ul}                      
  ------------------- ---------------- ------------------ ---------
  Acetylglycine       0.004            Allantoin          0.037
  Asparagine          0.002            Asparagine         0.027
  Biotine             0.003            Carnitine          0.027
  Choline             0.015            Glycocholine       0.042
  Dimethylglycine     0.048            Cystathionine      1.0E‐3
  Glutamic acid       0.034            Glutamic acid      0.005
  Glycerate           0.031            Glycine            0.037
  Glycine             0.026            Guanidinoacetate   0.021
  Homocysteine        0.030            Histidine          0.002
  Hydrooxyguanosine   0.011            Hydroxyguanosine   2.4E‐05
  Isoleucine          0.025            Kynurenic acid     0.024
  Kynurenic acid      0.006            kynurenine         0.043
  Leucine             0.025            Methyl succinate   0.006
  Methyl succinate    0.001            Phenylalanine      0.034
  Ornithine           0.007            Serine             0.005
  Serine              0.036            TMA                0.041
  Sorbitol            0.036            Urate              0.041
  Tyrosine            0.038            Xanthine           0.033
  Urate               0.003                               
  Valine              0.022                               

Linear regression model includes age, acculturation score, nativity, years living in U.S., BMI, HbA1C, sedentary lifestyle, sitting time, and biospecimen storage time.

###### 

Association of metabolites with BMI at baseline in the training and testing cohorts at baseline[\*](#osp463-note-0002){ref-type="fn"}

                     Training   Testing            
  ------------------ ---------- --------- -------- -------
  Methyl succinate   ‐4.35%     0.001     ‐3.82%   0.006
  Asparagine         ‐4.11%     0.002     ‐4.14%   0.027
  Urate              3.92%      0.003     3.60%    0.041
  Kynurenic acid     3.34%      0.006     4.06%    0.024
  Glycine            ‐2.91%     0.026     ‐3.79%   0.037
  Glutamic acid      2.54%      0.034     5.06%    0.005
  Serine             ‐2.29%     0.036     ‐4.88%   0.005

. Linear regression model includes age, acculturation score, nativity, years living in U.S., BMI, HbA1C, sedentary lifestyle, sitting time, and biospecimen storage time.

. Effect size indicates the percentage change in standard deviation in metabolite levels per one BMI unit increase for BMI.

We further investigated whether levels of metabolites differed by BMI category. In the training cohort, 20 metabolites were significantly different by BMI category (Table [4](#osp463-tbl-0004){ref-type="table-wrap"}). Among them, 8 remained significant in the testing cohort. They were Urate (P = 0.001 and 0.043), Methyl succinate (P = 0.004 and 0.015), Glutamic acid (P = 0.007 and 0.003), Asparagine (P = 0.008 and 0.047), Glycine (P = 0.010 and 0.047), and Acetyl glycine (P = 0.027 and 0.008), Serine (P = 0.028 and 0.006), and Kynurenic acid (P = 0.045 and 0.025). The levels of the top 4 validated significant metabolites by BMI category in the training cohort were shown in Figure [1](#osp463-fig-0001){ref-type="fig"}.

###### 

Association of metabolites with BMI category at baseline in the training and testing cohorts[\*](#osp463-note-0004){ref-type="fn"}

  Training           Testing                      
  ------------------ --------- ------------------ -------
  Acetoacetate       0.045     Acetyl glycine     0.008
  Acetyl glycine     0.027     Asparagine         0.047
  Asparagine         0.008     Carnitine          0.043
  Carnitine          0.020     Cystathionine      0.031
  Glucose            0.031     Glutamic acid      0.003
  Glutamic acid      0.007     Glycine            0.047
  Glycine            0.010     Guanidinoacetate   0.036
  Guanidinoacetate   0.011     Hydroxyguanosine   0.023
  Histidine          0.044     Kynurenic acid     0.025
  Homocysteine       0.011     kynurenine         0.043
  Isoleucine         0.028     Methyl succinate   0.015
  Kynurenic acid     0.045     Phenylalanine      0.024
  Leucine            0.028     Serine             0.006
  Methyl succinate   0.004     TMA                0.043
  Nitrotyrosine      0.033     Urate              0.043
  Ornithine          0.012     Xanthine           0.027
  Serine             0.028                        
  Tyrosine           0.001                        
  Urate              0.001                        
  Valine             0.019                        

Linear regression model includes age, acculturation score, nativity, years living in U.S., BMI, HbA1C, sedentary lifestyle, sitting time, and biospecimen storage time.

![Box‐plot of top 4 metabolites differed by BMI category in the discovery cohort. BMI category is defined as 0: normal weight (\<25); 1: overweight (25‐29.90); 2: class I obesity (30‐34.90); 3: class II obesity (35‐39.90); 4: class III obesity (40 and above).](OSP4-2-309-g001){#osp463-fig-0001}

Further, we explored whether metabolite levels at baseline might prospectively predict significant weight gain during 5‐year follow‐up. In the training and testing cohorts, 55 (28.2%) and 22 (22.0%) study subjects, respectively, were observed to have an increase in BMI category during the 5‐year follow‐up. In the training cohort, a total of 22 metabolites were observed to predict significant weight gain during follow‐up after adjusting for age, acculturation, nativity, years living in U.S., baseline BMI, HbA1c, sedentary lifestyle, sitting time, and biospecimen storage time (Table [5](#osp463-tbl-0005){ref-type="table-wrap"}). The most significant metabolite based on P value was Acetylcholine (P \< 1.0E‐05). With one standard deviation in levels of Acetylcholine increase, the risk of having significant weight gain during follow‐up was doubled (HR = 2.07, 95% CI: 1.44, 2.99). In the testing cohort, 6 of the 22 significant metabolites from the training cohort were validated. They were Acetylcholine, Leucine, Hippuric acid, Acetylglycine, Urate, and Xanthine. An elevated risk of significant weight gain during follow‐up was associated with High levels of Acetylcholine, Leucine, Acetylglycine, and Urate, but with reduced levels of Hippuric acid and Xanthine. In the testing cohort, when all 6 metabolites were included in the model together, the risk of having significant weight gain during follow‐up remained significant for Leucine (HR = 1.49, 95%CI: 1.05, 3.56), Hippuric acid (HR = 0.78, 95%CI: 0.45, 0.89), and Urate (HR = 1.46, 95%CI: 1.08, 2.43) (Table [6](#osp463-tbl-0006){ref-type="table-wrap"}). For all 6 metabolites, same analysis was performed using BMI as a continuous variable. Similar associations were observed (data not shown).

###### 

Individual metabolites predicting significant weight gain during follow‐up[\*](#osp463-note-0005){ref-type="fn"}

  Metabolites                  HR (95%CI)[\#](#osp463-note-0006){ref-type="fn"}   P value         HR (95%CI)[\#](#osp463-note-0006){ref-type="fn"}   P value
  ---------------------------- -------------------------------------------------- --------------- -------------------------------------------------- -----------
  **Acetylcholine**            **2.07 (1.44, 2.99)**                              **\<1.0E‐05**   **1.46 (1.07, 4.55)**                              **0.032**
  Transaconitic acid           2.11 (1.36, 3.04)                                  1.80E‐05        1.43 (0.85, 4.69)                                  0.142
  **Leucine**                  **2.23 (1.31, 3.80)**                              **5.10E‐05**    **1.54 (1.09, 5.23)**                              **0.025**
  Aminoadipic acid             1.36 (1.13, 1.64)                                  2.24E‐04        1.73 (0.78, 4.32)                                  0.265
  Leucic acid                  1.50 (1.22, 1.83)                                  4.48E‐04        1.32 (0.56, 1.86)                                  0.548
  Methyladenosine              1.48 (1.17, 1.72)                                  4.65E‐04        1.24 (0.73, 2.57)                                  0.436
  Pantothenic acid             1.25 (1.19, 1.57)                                  0.001           1.09 (0.54, 1.73)                                  0.642
  Betaine                      1.72 (1.21, 2.45)                                  0.002           1.44 (0.73, 2.32)                                  0.473
  **Hippuric acid**            **0.80 (0.29, 0.90)**                              **0.003**       **0.77 (0.52, 0.95)**                              **0.029**
  Hydroxyguanosine             1.96 (1.21, 3.15)                                  0.005           1.35 (0.81, 3.06)                                  0.352
  Cysteamine                   1.29 (1.14, 1.67)                                  0.006           1.05 (0.73, 1.89)                                  0.436
  **Acetylglycine**            **1.44 (1.13, 1.63)**                              **0.008**       **1.56 (1.01, 2.78)**                              **0.040**
  **Urate**                    **1.54 (1.18, 3.07)**                              **0.008**       **1.53 (1.09, 2.87)**                              **0.025**
  Alphadglucuronic acid        1.75 (1.25, 2.18)                                  0.009           1.23 (0.73, 2.79)                                  0.658
  TMA                          1.39 (1.11, 1.92)                                  0.018           1.09 (0.64, 4.52)                                  0.821
  Fructose                     1.27 (1.08, 1.95)                                  0.018           1.31 (0.88, 2.54)                                  0.169
  Glucose                      1.26 (1.06, 2.02)                                  0.02            1.29 (0.84, 3.02)                                  0.243
  Guanidinoacetate             0.60 (0.38, 0.92)                                  0.021           0.69 (0.35, 1.04)                                  0.077
  (s)‐b‐Aminoisobutyric acid   1.41 (1.05, 1.89)                                  0.024           1.03 90.56, 2.46)                                  0.872
  Carnitine                    1.43 (1.03, 2.01)                                  0.032           0.89 (0.41, 2.09)                                  0.764
  **Xanthine**                 **0.62 (0.39, 0.79)**                              **0.035**       **0.55 (0.34, 0.97)**                              **0.031**
  Glycocholate                 1.24 (1.04, 1.53)                                  0.038           1.05 (0.82, 1.25)                                  0.762

. Cox hazard regression was performing adjusting age, acculturation score, nativity, years living in U.S., baseline BMI, HbA1C, sedentary lifestyle, sitting time, and biospecimen storage time.

. The hazard ratio and 95% confidence interval were calculated as one standard deviation in levels of the individual metabolite increase.

###### 

Combined analysis to identify metabolites predicting weight gain during follow‐up[\*](#osp463-note-0007){ref-type="fn"}

  metabolite          HR (95% CI)[\#](#osp463-note-0008){ref-type="fn"}   P value
  ------------------- --------------------------------------------------- -----------
  **acetylcholine**   **1,64 (1.06, 3.42)**                               **0.022**
  Leucine             1.49 (0.90, 3.56)                                   0.073
  **hippuric acid**   **0.78 (0.45, 0.89)**                               **0.004**
  acetylglycine       1.15 (0.73, 1.98)                                   0.436
  **Urate**           **1.46 (1.08, 2.43)**                               **0.032**
  xanthine            0.87 (0.41, 1.80)                                   0.621

. Cox hazard regression was performing adjusting age, acculturation score, nativity, years living in U.S., baseline BMI, HbA1C, sedentary lifestyle, sitting time, and biospecimen storage time.

. The hazard ratio and 95% confidence interval were calculated as one standard deviation in levels of the individual metabolite increase.

Discussion {#osp463-sec-0011}
==========

In the current study with 300 Mexican American non‐smoking healthy women, we identified 7 metabolites associated with baseline BMI. Furthermore, we identified 6 metabolites, namely, Acetylcholine, Leucine, Hippuric acid, Acetylglycine, Urate, and Xanthine that predicted significant weight gain during 5‐year follow‐up. In further combined analysis with all 6 metabolites in the model, Acetylcholine, Hippuric acid, and Urate remained significant.

Overall, our findings of BMI associated metabolites are consistent with previous findings in non‐Hispanic populations [10](#osp463-bib-0010){ref-type="ref"}, [22](#osp463-bib-0022){ref-type="ref"}, [23](#osp463-bib-0023){ref-type="ref"}. Of 37 metabolites significantly associated with BMI in a meta‐analysis by Moore et al. [10](#osp463-bib-0010){ref-type="ref"}, 13 were analyzed in the current study. Among them, 9 and 7 were significantly associated with BMI in the training and testing cohorts, respectively. And 4 were significant in both cohorts. In addition to those 4 metabolites, we observed 3 more significant metabolites, namely Urate, Serine, and Methylsuccinate. The linear positive relationship between serum Urate and BMI is previously reported in several population‐based studies [22](#osp463-bib-0022){ref-type="ref"}, [24](#osp463-bib-0024){ref-type="ref"}. In a study among youth with obesity and type‐2 diabetes, Mihalik et al. reported that Serine levels in fasting plasma were inversely associated with BMI [23](#osp463-bib-0023){ref-type="ref"}. The only metabolite whose association with BMI has not been reported previously is Methylsuccinate. Methylsuccinate is involved in Isoleucine catabolism [25](#osp463-bib-0025){ref-type="ref"}. Previous work also demonstrated that methyl esters of succinate are potent insulin secretagogues in pancreatic islets [26](#osp463-bib-0026){ref-type="ref"}. On the other hand, Newgard et al. compared urinary levels of Methylsuccinate between obese and lean individuals and found no difference [11](#osp463-bib-0011){ref-type="ref"}. Clearly, further assessment of the relationship between Methylsuccinate and BMI is needed.

In the individual metabolite analysis, we identified a total of 6 metabolites that could predict significant weight gain during follow‐up. And 3 of them remained significant when we included all 6 metabolites in multivariate analysis. Among them, Urate was the only metabolite that was significantly associated with BMI and also predicted significant weight gain. This may suggest the metabolic profile associated with BMI may not overlap with the one predicting weight gain. Given how quickly the individuals can gain significant amount of weight, research particularly focusing on metabolites predicting weigh gain is urgently needed.

Of the highest significance is the positive association between Acetylcholine levels and risk of significant weight gain. Our observation is consistent with the role of Acetylcholine in metabolic regulation. Acetylcholine is a neurotransmitter derived from an ester of acetic acid and choline. The central and peripheral Acetylcholine system plays a very important role in glucose and energy homeostasis [27](#osp463-bib-0027){ref-type="ref"}. In animal models of obesity and hyperinsulinemia, obesity could lead to enhanced Acetylcholine release from neurons [27](#osp463-bib-0027){ref-type="ref"}, [28](#osp463-bib-0028){ref-type="ref"}, [29](#osp463-bib-0029){ref-type="ref"}. More interestingly, in feeding studies, a possible link of choline, Acetylcholine, and obesity/diabetes has been suggested [30](#osp463-bib-0030){ref-type="ref"}, [31](#osp463-bib-0031){ref-type="ref"}, [32](#osp463-bib-0032){ref-type="ref"}. Wu et al. found that choline deficiency attenuates body weight gain and improves glucose tolerance in obese mice [32](#osp463-bib-0032){ref-type="ref"}. Acetylcholine exerts its functions by binding to two cell‐surface receptors: the nicotinic and muscarinic acetylcholine receptors [27](#osp463-bib-0027){ref-type="ref"}. In American Indians, Zhu et al. reported that multiple variants in the nicotinic acetylcholine receptor gene family were jointly associated with abdominal obesity, independent of general obesity and cigarette smoking per se. Interestingly, In recent studies, the potential of muscarinic acetylcholine receptors as a therapeutic target of obesity has been proposed [33](#osp463-bib-0033){ref-type="ref"}, [34](#osp463-bib-0034){ref-type="ref"}.

Our observation of an inverse association between Hippuric acid and risk of significant weight gain is consistent with a previous report that urinary levels of Hippuric acid were significantly lower in obese individuals than normal weight controls [35](#osp463-bib-0035){ref-type="ref"}. Hippuric acid is a gut flora‐derived metabolite from low‐molecular‐weight aromatic compounds and polyphenols generated by a range of gut microbes [36](#osp463-bib-0036){ref-type="ref"}. Urinary levels of Hippuric acid have been shown to correlate with the obese phenotype in different animal models and to associate with the fecal counting of several bacterial species in a rat model of obesity [37](#osp463-bib-0037){ref-type="ref"}, [38](#osp463-bib-0038){ref-type="ref"}, [39](#osp463-bib-0039){ref-type="ref"}. Thus, the observed relationship in the current study may suggest a link between gut microflura metabolism and obesity phenotype. Recent works have shown that obesity is associated with phylum‐level changes in the microbiota, reduced bacterial diversity, and altered representation of bacterial genes and metabolic pathways [40](#osp463-bib-0040){ref-type="ref"}, [41](#osp463-bib-0041){ref-type="ref"}. On the other hand, gut microbiome may modulate metabolic pathways, lead to weight loss and eventually reduce the obese burden [42](#osp463-bib-0042){ref-type="ref"}.

Both Xanthine and Urate were associated with significant weight gain, but at different directions. This is consistent with the biological function of these two metabolites since Xanthine is converted to Urate by the action of the xanthine oxidase enzyme. In our study, Xanthine is highly correlated with Urate (ρ = 0.672, P \< 0.001). Recent studies show that fructose‐induced Urate generation causes mitochondrial oxidative stress that stimulates fat accumulation independent of excessive caloric intake [43](#osp463-bib-0043){ref-type="ref"}. Interestingly, we also observed a significant positive relationship between Fructose and significant weight gain in the training cohort. Fructose may increase the risk for weight gain by altering satiety, resulting in increased food intake. Thus, the results from this study support the roles of Urate and Fructose in obesogenic development.

The positive association between circulating levels of Leucine and BMI has been reported previously [10](#osp463-bib-0010){ref-type="ref"}, [11](#osp463-bib-0011){ref-type="ref"} as well as in the discovery cohort. Leucine has also been reported as a predictor for type‐2 diabetes [11](#osp463-bib-0011){ref-type="ref"}, [14](#osp463-bib-0014){ref-type="ref"}. However, no study has reported Leucine as a positive predictor for weight gain. Acetylglycine levels were inversely associated with baseline BMI (P = 0.061 and 0.022 in the discovery and validation cohorts, respectively). However, we found high Acetylglycine levels were associated with increased risk of significant weight gain. Among functionally‐limited adults, Lustgarten et al. reported Acetylglycine was positively associated with dietary fiber intake, muscle strength, and mobility. However, dietary fiber has been frequently linked to aid in energy intake control and reduced risk for development of obesity. Unfortunately, we don\'t have dietary intake data on those study participants.

Several potential limitations should be considered. The study sample size of 300 total participants is relatively small. Considering that the effect size of many metabolites may be very small [44](#osp463-bib-0044){ref-type="ref"}, some of the associations may not be detected in the current study. Our metabolomics analysis was limited to metabolites that could be detected by the platforms used and our data were measured in terms of relative concentrations rather than actual concentrations. In addition, the metabolite levels in our study were based on blood samples from a single point in time that may not reflect the true associations over time. Nevertheless, this is the first metabolomics study to identify metabolites associated with BMI and to further discover metabolites prospectively predicting weight gain in Mexican Americans. Our results provide strong rationales for future large prospective studies to further clarify the associations among obesity/weight gain, metabolites, and chronic disease risks.
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